The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Oct. 28, 1:44 PM

Slide #20. Sunesis Pharmaceuticals, Inc. Secondary Offering

Company: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Date announced: 10/18/2016
Secondary Offering Details: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series C Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offering for clinical development of SNS-062, regulatory development of vosaroxin in Europe and other general corporate purposes.

Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. QINPREZO™ (vosaroxin) is Co.'s product candidate for the treatment of acute myeloid leukemia. Co. owns worldwide development and commercialization rights to vosaroxin. Also, Co.'s development pipeline include: TAK-280, an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors; SNS-062, for treatment of B-cell malignancies and other blood cancers; and SNS-229 / SNS-510 for hematologic and solid tumor malignancies.
Open the SNSS Page at The Online Investor »

Company Name:  Sunesis Pharmaceuticals Inc
Sector:  Biotechnology
Number of ETFs Holding SNSS:  1
Total Market Value Held by ETFs:  $10555
Total Market Capitalization:  $55.00M
% of Market Cap. Held by ETFs:  0.02%

Open the SNSS Page at The Online Investor (in a new window) »

October 28, 2016    1:44 PM Eastern
Quotes delayed 20 minutes

Buy (3.33 out of 4)
62nd percentile
(ranked higher than approx. 62% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.